Matches 1 - 50 out of 106 1 2 3 >


Match Document Document Title
9023319 Vaccine  
Provided herein are methods for immunizing children under six months of age by administering to the child a pharmaceutical composition comprising at least one antigen derived from an influenza virus.
8986709 Vaccine for prophylaxis or treatment of an allergen-driven airway pathology  
The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for...
8956625 Inactivated polio vaccines  
The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis...
8916173 Acellular pertussis vaccine  
Described are acellular pertussis (aP) vaccine compositions comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and...
8728491 Transcutaneous delivery of therapeutic agents  
The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to...
8574589 Antigen purification process for pertactin antigen  
Bordetella pertussis p69 antigen is purified by immobilized metal affinity chromatography.
8574596 Pertussis antigens and use thereof in vaccination  
The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic,...
8569470 Engineered pertactin variants for vaccine use  
The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part...
8465754 Bordetella parapertussis whole-cell vaccine composition  
An objective of the present invention is to provide a whole-cell bacterial vaccine composition for preventing whooping cough caused by Bordetella parapertussis, comprising whole cells, whole-cell...
8431160 Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions  
Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide...
8048433 Deacylation of LPS in gram negative bacteria  
The current invention provides new Gram negative polypeptides exhibiting lipid A 3-O-deacylase activity and are capable of modifying and/or detoxifying gram negative LPS. The present invention...
7981434 Surface exposed immunoglobulin D-binding protein from Moraxella catarrhalis  
The present invention relates to a surface exposed protein, which can be detected in Moraxella catarrhalis, having an amino acid sequence as described in SEQ ID NO: 1, an apparent molecular weight...
7670830 Trichoderma spp strains with high capacity of fungus biological control and selection process thereof by molecular markers  
Trichoderma spp. strains with high capacity for fungus biological control in wide ranges of temperature and pH are described, such strains being compatible with each other. Likewise, a process of...
7485304 Non-toxic mucosal adjuvant  
A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic...
7465443 Acellular antibordetella vaccine  
The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of...
7427404 Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines  
New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the aminoacid residues Glu129, Asp11, Trp26,...
7285289 Nanoparticle vaccines  
The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed...
7279169 Mucosal DTPa vaccines  
Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT)...
7211263 Use of adenylate cyclase or bacteria producing it as vaccines against Bordetella  
The invention relates to a method of immunizing a mammal against infection by a first Bordetella species. The method comprises administering to the mammal a preparation comprising a portion of the...
RE39494 Inactivated mycoplasma hyopneumoniae and uses therefor  
The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of...
7105161 Proteinaceous adjuvants  
A modulated immune response to an antigen is achieved by coadministering the antigen and a genetically-detoxified pertussis holotoxin, particularly one retaining its immunogenicity, to a host. The...
7105317 Immunogenic compositions comprising vrg-gene products from Bordetella extracts  
This invention relates to an immunogenic composition comprising a bacterial extract containing at least one expression products of the vrg genes of a strain of Bordetella chosen from B. pertussis,...
7087236 Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof  
A method of inducing either a TH1 polarized immune response, a TH2 polarized immune response or a combined TH1 and TH2 response to an antigen and associated vaccine formulations are disclosed. A...
7070781 Nontoxic mucosal adjuvant  
A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic...
7070779 POLYPEPTIDES CONTAINING POLYMORPHISMS OF THE REPEATED REGIONS OF PERTACTIN IN BORDETELLA PERTUSSIS, BORDETELLA PARAPERTUSSIS, AND BORDETELLA BRONCHISEPTICA, THEIR USE IN DIAGNOSTICS, AND IN IMMUNOGENIC COMPOSITIONS  
Pertactin (PRN) is an outer membrane protein expressed by Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica, which induces protective immunity to Bordetella infections....
7056521 Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants  
The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E....
6929794 IL-12 as an adjuvant for Bordetella pertussis vaccines  
This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection....
6890530 Composition comprising fungi of genus trichoderma used as biological control agent and the applications thereof  
The composition includes fingi belonging to one or more species of fungi of the genus Trichoderma, selected from T. asperellum, T. atroviride, T. inhamatum and their mixtures, useful as an agent...
6887484 Vaccine composition containing a promoter peptide  
A vaccine having a good vaccination effect, which comprises an antigen; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having...
6814971 Adjuvants for use in vaccines  
The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local...
6696065 Acellular pertussis vaccines and methods of preparation thereof  
A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain...
6660261 Bordetella strain expressing the FHA hybrid, liposomes and vaccines  
The invention concerns a Bordetella strain deficient in the production of toxin and expressing a hybrid protein comprising at least part of the filamentous hemagglutin (FHA) and at least part of a...
6562352 Vaccine compositions for mucosal delivery  
The invention provides the use of an antigen which is a mucosally immunogenically active substance comprising the 50 kD C fragment of tetanus toxin, an immunogenic fragment thereof, or a...
6517844 Compositions and method for immunizing polutry  
The present invention is directed to vaccine compositions and methods for immunizing poultry. The vaccine compositions comprise inactivated bacterial organisms which can be administered to the...
6399076 Acellular pertussis vaccines and methods of preparation thereof  
Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70% of members...
6368589 Use of autologous promoters to express gene products in Bordetella  
Autologous promoters are used to effect expression of gene products in Bordetella strains. Hybrid Bordetella genes are constructed comprising a Bordetella gene, particularly one encoding a...
6284256 Bordetella bronchiseptica vaccine  
The present invention is concerned with a vaccine for combating B. bronchiseptica infection in susceptible animals (such as dogs and swine), containing proteins or polypeptides typical of the...
6251606 Gene sequence and method for distinguishing cordyceps sinensis  
The present invention utilizes the singularity of the 18S rRNA gene sequence of the Cordyceps sinensis between the NS3/NS6 primer pair as the index for distinguishing the Cordyceps sinensis from...
6210685 Antigenic preparations and isolation of such preparations  
The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of B. pertussis, the said preparations being...
6162433 Non antibiotic selectable markers for live vaccines  
The invention relates to DNA constructs encoding a safe, selectable marker, other than an antibiotic resistance marker, vectors and/or cells including said constructs; and vaccines based on said...
6127151 Antigenic preparations and the isolation of such preparations  
A method of deriving an antigen from Bordetella pertussis, wherein the antigen is characterized by the following features: a relative molecular weight of about 67,000 to 73,000 as determined by...
6060067 Process for the preparation of tetanus toxoid vaccine  
PCT No. PCT/GB93/01037 Sec. 371 Date Mar. 1, 1995 Sec. 102(e) Date Mar. 1, 1995 PCT Filed May 20, 1993 PCT Pub. No. WO94/03206 PCT Pub. Date Feb. 17, 1994A process for the preparation of tetanus...
6046224 12 (S)--hete receptor blockers  
The 12-lipoxygenase product, 12(S)-HETE, mediates hyperproliferative and hyperplastic responses seen in atherosclerosis, diabetes, Parkinson's disease, Alzheimer's, stroke-induced nerve damage and...
6030625 Bordetella pertussis and Bordetella parapertussis strains  
An immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (Ac-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of Bordetella chosen from B....
6019979 Anti-viral treatment with pertussis toxin B oligomer  
There is disclosed a method for anti-viral therapy treatment with the Pertussis toxin beta subunit oligomer, wherein the oligomer is composed of from two to ten subunits of PTX selected from the...
5989564 Pertussis toxoid made by reacting pertussis toxin with the nitrating agent TNM  
A toxoid of pertussis toxin in which the pertussis toxin is modified essentially only at one or more tyrosine residues, as by the use of a nitrating agent such as tetranitromethane or by...
5985286 Bordetella strains  
The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of...
5980907 Vaccines containing bacteria attenuated by mutation of the htrA gene  
Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which...
5976544 Polypeptides and vaccines for Bordetellapertussis and method of use  
A polypeptide for use in a vaccine against Bordetella pertussis, B. parapertussis or B. bronchiseptica contains an epitope selected from (a) the amino acid sequence coded for by nucleotides 1885...
5965385 Modification of pertussis toxin  
The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin...

Matches 1 - 50 out of 106 1 2 3 >